Iron chelation therapy
Open Access
- 1 July 1997
- journal article
- research article
- Published by Wiley in Journal of Internal Medicine
- Vol. 242 (S740) , 37-41
- https://doi.org/10.1111/joim.1997.242.s740.37
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overloadBritish Journal of Haematology, 1996
- A novel delivery system for continuous desferrioxamine infusion in transfusional iron overloadBritish Journal of Haematology, 1996
- Results of Long-Term Iron-Chelating TherapyActa Haematologica, 1996
- Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron ChelatorsBritish Journal of Haematology, 1995
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorNew England Journal of Medicine, 1994
- Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.Journal of Clinical Pathology, 1994
- Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trialBritish Journal of Haematology, 1992
- Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patientsThe Lancet, 1990
- Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.BMJ, 1987
- 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE, AN ORALLY ACTIVE CHELATOR FOR TREATMENT OF IRON OVERLOADThe Lancet, 1987